Boehringer Ingelheim and Vitae in $242 million Alzheimer's deal
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and Vitae Pharmaceuticals are to develop new Alzheimer's disease treatments based on beta-secretase (BACE) inhibitors in a deal worth up to $242 million.